Chemotherapy and Persistent Depression in Older Mexican Cancer Survivors: Secondary Analysis of the Mexican Health and Aging Study.

IF 1.9 4区医学 Q3 ONCOLOGY

Cancer Investigation Pub Date : 2025-06-25 DOI:10.1080/07357907.2025.2521693

Diego Arriaga-Izabal, Francisco Morales-Lazcano, Adrián Canizalez-Román

{"title":"Chemotherapy and Persistent Depression in Older Mexican Cancer Survivors: Secondary Analysis of the Mexican Health and Aging Study.","authors":"Diego Arriaga-Izabal, Francisco Morales-Lazcano, Adrián Canizalez-Román","doi":"10.1080/07357907.2025.2521693","DOIUrl":null,"url":null,"abstract":"Introduction: Depressive symptoms (DS) are prevalent among cancer survivors and may be exacerbated by chemotherapy. However, longitudinal data on this relationship within the Mexican population are lacking. The current study aimed to analyze the relationship between chemotherapy and the persistence of depressive symptoms over time in cancer survivors.Methods: Retrospective observational study using Mexican Study of Health and Aging (MHAS) data (2012-2021). Participants aged 50+ included chemotherapy patients (n = 30) and healthy controls (n = 6,970). Depressive symptoms were assessed with a modified Center for Epidemiologic Studies Depression Scale. Mann-Whitney U, X2 tests, and generalized estimating equations analyzed chemotherapy's impact on depressive symptoms over time.Results: Chemotherapy recipients showed significantly higher depressive symptoms at early follow-ups (2012, 2015, 2018; p < 0.05), with no significant difference by 2021. Adjusted analyses indicated chemotherapy was associated with a more than twofold increase in odds of depression (OR = 2.165; 95% CI: 1.220-3.810). Lower education and comorbidities such as diabetes and hypertension were also independently linked to increased depression risk.Conclusions: Chemotherapy is a significant predictor of persistent depressive symptoms among Mexican cancer survivors aged 50 and above. These findings highlight the critical need for integrated mental health screening and targeted psychosocial care within oncology settings.","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"1-9"},"PeriodicalIF":1.9000,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/07357907.2025.2521693","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Depressive symptoms (DS) are prevalent among cancer survivors and may be exacerbated by chemotherapy. However, longitudinal data on this relationship within the Mexican population are lacking. The current study aimed to analyze the relationship between chemotherapy and the persistence of depressive symptoms over time in cancer survivors.

Methods: Retrospective observational study using Mexican Study of Health and Aging (MHAS) data (2012-2021). Participants aged 50+ included chemotherapy patients (n = 30) and healthy controls (n = 6,970). Depressive symptoms were assessed with a modified Center for Epidemiologic Studies Depression Scale. Mann-Whitney U, X² tests, and generalized estimating equations analyzed chemotherapy's impact on depressive symptoms over time.

Results: Chemotherapy recipients showed significantly higher depressive symptoms at early follow-ups (2012, 2015, 2018; p < 0.05), with no significant difference by 2021. Adjusted analyses indicated chemotherapy was associated with a more than twofold increase in odds of depression (OR = 2.165; 95% CI: 1.220-3.810). Lower education and comorbidities such as diabetes and hypertension were also independently linked to increased depression risk.

Conclusions: Chemotherapy is a significant predictor of persistent depressive symptoms among Mexican cancer survivors aged 50 and above. These findings highlight the critical need for integrated mental health screening and targeted psychosocial care within oncology settings.

查看原文本刊更多论文

墨西哥老年癌症幸存者的化疗和持续抑郁：墨西哥健康与衰老研究的二次分析

抑郁症状（DS）在癌症幸存者中很普遍，并可能因化疗而加重。然而，在墨西哥人口中缺乏这种关系的纵向数据。目前的研究旨在分析化疗与癌症幸存者持续抑郁症状之间的关系。方法：采用墨西哥健康与老龄化研究（MHAS）数据（2012-2021）进行回顾性观察研究。50岁以上的参与者包括化疗患者（n = 30）和健康对照（n = 6,970）。用改良的流行病学研究中心抑郁量表评估抑郁症状。Mann-Whitney U、X2检验和广义估计方程分析了化疗随时间推移对抑郁症状的影响。结果：化疗患者在早期随访时抑郁症状明显升高(2012年、2015年、2018年；结论：化疗是50岁及以上墨西哥癌症幸存者持续抑郁症状的重要预测因子。这些发现强调了在肿瘤环境中进行综合心理健康筛查和有针对性的社会心理护理的迫切需要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Investigation 医学-肿瘤学

CiteScore

3.80

自引率

4.20%

发文量

审稿时长

8.5 months

期刊介绍： Cancer Investigation is one of the most highly regarded and recognized journals in the field of basic and clinical oncology. It is designed to give physicians a comprehensive resource on the current state of progress in the cancer field as well as a broad background of reliable information necessary for effective decision making. In addition to presenting original papers of fundamental significance, it also publishes reviews, essays, specialized presentations of controversies, considerations of new technologies and their applications to specific laboratory problems, discussions of public issues, miniseries on major topics, new and experimental drugs and therapies, and an innovative letters to the editor section. One of the unique features of the journal is its departmentalized editorial sections reporting on more than 30 subject categories covering the broad spectrum of specialized areas that together comprise the field of oncology. Edited by leading physicians and research scientists, these sections make Cancer Investigation the prime resource for clinicians seeking to make sense of the sometimes-overwhelming amount of information available throughout the field. In addition to its peer-reviewed clinical research, the journal also features translational studies that bridge the gap between the laboratory and the clinic.